JonathanBernsteinMD

Pediatric Hematology & Oncology • Hershey, PA

Pediatric Anemia and Red Blood Cell Hematology, Pediatric Coagulation Disorder Hematology, Pediatric Hematologic Oncology, Pediatric Neuro-Oncology

Director of Pediatric hematology and the pediatric Hemophilia Treatment Center doctor at Penn St Hershey

Join to view full profile

Dr. Bernstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bernstein's full profile

Already have an account?

Office
500 University Dr
Hershey, PA 17033
Phone+1 702-236-6116
Is this information wrong?

Summary

I am a pediatric hematologist oncologist specializing in caring for adults and children with bleeding and clotting disorders, menorrhagia, as well as rare blood disorders. These include pyruvate kinase deficiency, sickle cell, thalassemia, and other hematologic disorders.
I also care for patients with vascular anomalies including Klippel Trenaunay Weber syndrome and Hereditary Hemorrhagic Telangiectasia.

Education & Training

Indiana University School of MedicineFellowship, Pediatric Hematology/Oncology, 1994 - 1997
Children's Hospital Los AngelesResidency, Pediatrics, 1991 - 1994
University of Rochester School of Medicine and DentistryClass of 1991
University of Southern CaliforniaM.S., Applied Biometry, 1985 - 1987
University of Southern CaliforniaNo Degree, Premedical Studies, 1983 - 1985
University of OregonB.S., History, 1980 - 1982
California State University, NorthridgeNo Degree, General Studies, 1977 - 1980

Certifications & Licensure

PA State Medical License 2020 - 2024
CA State Medical License 1993 - 2023
CT State Medical License 2016 - 2021
NV State Medical License 1997 - 2019

Awards, Honors, & Recognition

Top doctor Award Pediatric Hematology-Oncology 2016
American Red Cross � Everyday Hero Award - medical 2015
Las Vegas Chapter Outstanding Philanthropist Award Association of Fund Raising Professionals, 2010
Top doctor Award � Las Vegas Health Quarterly 2010-2016
Salute to Heros Award North Las Vegas Chamber of Commerce, 2008
Patient�s Choice Award 2008-2009
Top Doctor Award, Rheumatology Las Vegas Life Magazine, 2007
Most Enrollment Award CCOP, 2006
Faculty Teaching Award UNSOM Pediatric Residency Program, 2002, 2009
Top Doctor Award, Oncology Las Vegas Life Magazine, 2002, 2004, 2007
Sierra Health Consultant of the Year Award 2001
Student Fellowship Award American Cancer Society, Hammersmith Hospital, 1989
Medical Student Pathology Fellow University of Rochester School of Medicine and Dentistry, 1989
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Start of enrollment: 2001 Feb 01
Unknown status
Phase 3
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Start of enrollment: 2004 Mar 15
Completed
Phase 3
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
Completed
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Start of enrollment: 2004 Apr 01
Active, not recruiting
Phase 3
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14
Completed
Phase 3
Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission Start of enrollment: 2005 May 30
Completed
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Start of enrollment: 2006 Feb 20
Completed
Phase 3
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Start of enrollment: 2006 Jun 01
Completed
Phase 2
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Start of enrollment: 2007 Aug 06
Active, not recruiting
Phase 3
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Oct 30
Active, not recruiting
Phase 3
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Start of enrollment: 2006 Dec 26
Completed
Phase 3
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2007 Mar 01
Completed
Phase 3
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Start of enrollment: 2007 Feb 26
Active, not recruiting
Phase 3
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 3
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Start of enrollment: 2007 Jan 22
Active, not recruiting
Phase 3
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia Start of enrollment: 2007 Jan 01
Completed
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin Start of enrollment: 2007 May 01
Completed
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 Feb 04
Active, not recruiting
Phase 3
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Jan 15
Active, not recruiting
Phase 3
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers Start of enrollment: 2008 Jun 02
Completed
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Start of enrollment: 2008 Jun 23
Completed
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2009 Jan 01
Completed
Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Start of enrollment: 2009 Mar 09
Completed
Phase 3
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Start of enrollment: 2009 Mar 01
Completed
Phase 2
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
Completed
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Tissue From Young Patients With Cancer Start of enrollment: 2007 Mar 05
Recruiting
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma Start of enrollment: 2006 Oct 23
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Study of Blood Samples From Newborns With Down Syndrome Start of enrollment: 2009 Feb 23
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Start of enrollment: 2005 May 30
Completed
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Start of enrollment: 2010 Jan 01
Completed
Phase 2
Survey of Inhibitors in Plasma-Product Exposed Toddlers Start of enrollment: 2010 Jan 01
Completed
Phase 4
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Start of enrollment: 2010 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Start of enrollment: 2011 May 01
Completed
Not Applicable
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission Start of enrollment: 2012 Feb 21
Active, not recruiting
Phase 3
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
Active, not recruiting
Phase 2
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Start of enrollment: 2013 Jun 17
Active, not recruiting
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Active, not recruiting
Phase 2
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Start of enrollment: 2014 Aug 01
Completed
Phase 2
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
Active, not recruiting
Phase 2, Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
ATHN 8: Previously Untreated Patients (PUPs) Matter Study Start of enrollment: 2018 Oct 03
Completed
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Numerical Study on the Impact of Central Venous Catheter Placement on Blood Flow in the Cavo-Atrial Junction.
Boyang Su, Hannah Palahnuk, Thaddeus Harbaugh, Elias Rizk, Will Hazard, Angel Chan, Jonathan Bernstein, Jonathan W Weinsaft, Keefe B Manning> ;Annals of Biomedical Engineering. 2024 May 1
15 citations
Resolving Clinical Phenotypes into Endotypes in Allergy: Molecular and Omics Approaches.
Tesfaye B. Mersha, Yashira Afanador, Elisabet Johansson, Steven P. Proper, Jonathan A. Bernstein, Marc E. Rothenberg, Gurjit K. Khurana Hershey> ;Clinical Reviews in Allergy & Immunology. 2021 Apr 1
18 citations
Functional and structural analysis of cytokine selective IL6ST defects that cause recessive hyper-IgE syndrome
Yin-Huai Chen, Diane B. Zastrow, Riley D. Metcalfe, Lisa Gartner, Freia Krause, Craig J. Morton, Shruti Marwaha, Laure Fresard, Yong Huang, Chunli Zhao, Colleen E. McC...> ;The Journal of Allergy and Clinical Immunology. 2021 Mar 23
23 citations
Manifesto on United Airways Diseases (UAD): An Interasma (Global Asthma Association – GAA) document
Angelica Tiotiu, Plamena Novakova, Ilaria Baiardini, Andras Bikov, Herberto José Chong-Neto, Jaime Correia de-Sousa, Alexander Emelyanov, Enrico Heffler, Guillermo Gui...> ;The Journal of Asthma. 2021 Mar 5
77 citations
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asth...
Tim W Harrison, Pascal Chanez, Francesco Menzella, Giorgio Walter Canonica, Renaud Louis, Borja G. Cosío, Njira L Lugogo, Arjun Mohan, Annie Burden, L. McDermott, Esth...> ;The Lancet. Respiratory Medicine. 2021 Mar 1
47 citations
The global impact of the COVID-19 pandemic on the management and course of chronic urticaria.
Emek Kocatürk, Andac Salman, Ivan Cherrez-Ojeda, Paulo Ricardo Criado, Jonny Peter, Elif Comert-Ozer, Mohamed Abuzakouk, Rosana Câmara Agondi, Mona Al-Ahmad, Sabine Al...> ;Allergy. 2021 Mar 1
5 citations
A robust multiplexed assay to quantify C1-inhibitor, C1q, and C4 proteins for in vitro diagnosis of hereditary angioedema from dried blood spot.
Yongquan Lai, Guodong Zhang, Neil Inhaber, Jonathan A. Bernstein, Michael Cwik, Zhiwei Zhou, Priya S. Chockalingam, Jiang Wu> ;Journal of Pharmaceutical and Biomedical Analysis. 2021 Feb 20
10 citations
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: fi...
William R Lumry, Bruce Zuraw, Marco Cicardi, Timothy Craig, John Anderson, Aleena Banerji, Jonathan A Bernstein, Teresa Caballero, Henriette Farkas, Richard G Gower, P...> ;Orphanet Journal of Rare Diseases. 2021 Feb 15
Needs assessment: knowledge of self-management of asthma for children with co-morbid physical and intellectual disabilities: brief report.
Laura Nabors, Jonathan A. Bernstein, Tonya A Winders, Mary Hart, Filiberto Toledano-Toledano> ;The Journal of Asthma. 2021 Feb 9
107 citations
The global burden of chronic urticaria for the patient and society
Margarida Gonçalo, Ana Giménez-Arnau, Ma'moon M Al-Ahmad, Moshe Ben-Shoshan, Jonathan A. Bernstein, Luis Felipe Ensina, Daria Fomina, Cesar A Galvàn, Kiran Godse, Cliv...> ;The British Journal of Dermatology. 2021 Feb 1
1 citations
Atopic endotypes as a modulating factor for SARS-CoV-2 infection: mechanisms and implications.
Kyle S Huntley, Lauren Fine, Jonathan A. Bernstein> ;Current Opinion in Allergy and Clinical Immunology. 2021 Jan 19
3 citations
Biallelic UBE4A loss-of-function variants cause intellectual disability and global developmental delay.
Uirá Souto Melo, Devon Bonner, Kevin C K Lloyd, Ala Moshiri, Brandon J. Willis, Louise Lanoue, Lynette Bower, Brian C. Leonard, Davi Jardim Martins, Fernando Ribeiro G...> ;Genetics in Medicine. 2021 Jan 8
16 citations
"It seems like COVID-19 now is the only disease present on Earth": living with a rare or undiagnosed disease during the COVID-19 pandemic.
Meghan C. Halley, Talia Stanley, Jay Maturi, Aaron J. Goldenberg, Jonathan A. Bernstein, Matthew T. Wheeler, Holly K. Tabor> ;Genetics in Medicine. 2021 Jan 8
120 citations
US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema.
Paula J. Busse, Sandra C. Christiansen, Marc A. Riedl, Aleena Banerji, Jonathan A. Bernstein, Anthony J. Castaldo, Timothy J. Craig, Mark Davis-Lorton, Michael M. Fran...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2021 Jan 1
9 citations
Treatment of chronic spontaneous urticaria with benralizumab: Report of primary endpoint per‐protocol analysis and exploratory endpoints
Jonathan A. Bernstein, Umesh Singh, Marepalli B. Rao, Karen Berendts, Xiang Zhang, Diya F. Mutasim> ;Allergy. 2021 Apr 1
34 citations
Peanut allergy diagnosis: A 2020 practice parameter update, systematic review, and GRADE analysis.
Matthew Greenhawt, Marcus Shaker, Julie Wang, John Oppenheimer, Scott H. Sicherer, Corinne A. Keet, Keri R Swaggart, Matthew A. Rank, Jay M. Portnoy, Jonathan A. Berns...> ;The Journal of Allergy and Clinical Immunology. 2020 Dec 1
12 citations
L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond...
Adrianna Vlachos, Evangelia Atsidaftos, Mohammad Lutfi Lababidi, Ellen Muir, Zora R. Rogers, Waseem Alhushki, Jonathan Bernstein, Bertil Glader, Barbara Gruner, Helge ...> ;Pediatric Blood & Cancer. 2020 Dec 1
10 citations
The Utility of Resolving Asthma Molecular Signatures Using Tissue-Specific Transcriptome Data.
Debajyoti Ghosh, Lili Ding, Jonathan A. Bernstein, Tesfaye B. Mersha> ;G3. 2020 Nov 5
19 citations
Definition and classification of hereditary angioedema.
Steven P. Proper, William J. Lavery, Jonathan A. Bernstein> ;Allergy and Asthma Proceedings. 2020 Nov 1
63 citations
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial
Bruce L. Zuraw, William R. Lumry, Douglas T. Johnston, Emel Aygören-Pürsün, Aleena Banerji, Jonathan A. Bernstein, Sandra C. Christiansen, Joshua S. Jacobs, Karl Sitz,...> ;The Journal of Allergy and Clinical Immunology. 2020 Oct 21
4 citations
Association Between Self-Reported Dental Hygiene Practices and Dental Procedure-Related Recurrent Angioedema Attacks in HAE Subjects: A Multicenter Survey.
Umesh Singh, William R. Lumry, Paula J. Busse, H. James Wedner, Aleena Banerji, Timothy J. Craig, H. Henry Li, Raffi Tachdjian, Joshua S. Jacobs, Marc A. Riedl, Mark D...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2020 Oct 1
35 citations
Benralizumab for Chronic Spontaneous Urticaria.
Jonathan A. Bernstein, Umesh Singh, Marepalli B. Rao, Karen Berendts, Xiang Zhang, Diya F. Mutasim> ;The New England Journal of Medicine. 2020 Sep 30
6 citations
Beliefs and preferences regarding biological treatments for severe asthma
Andras Bikov, Ipek Kivilcim Oguzulgen, Ilaria Baiardini, Marco Contoli, Alexander Emelyanov, Omar Fassio, Juan Carlos Ivancevich, Igor Kaidashev, Krzysztof Kowal, Mari...> ;The World Allergy Organization Journal. 2020 Jul 1
1 citations
Drug-induced anaphylaxis and drug sales: Why the discordance?
Edgardo Jares, Alicia De Falco, Mario Sánchez-Borges, Jonathan A. Bernstein, Andrea Zanacchi, Silvana Monsell, René Maximiliano Gómez> ;Annals of Allergy, Asthma & Immunology. 2020 Jun 21
3 citations
Influence of alexithymia on the management of Latin American patients with asthma: A cross-sectional study.
Emanuel Vanegas, Miguel Felix, German D. Ramon, Orlando Lopez Jove, Edgar Emilio Matos Benavides, Iván Tinoco-Morán, Jonathan A. Bernstein, Ivan Cherrez-Ojeda> ;SAGE Open Medicine. 2020 Jun 7
Join now to see all

Journal Articles

Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease
Carlos A Bacino, Vandana Shashi, Euan A Ashley, Cynthia J Tifft, William A Gahl, Brendan H Lee, John J Mulvihill, Rizwan Hamid, Matthew T Wheeler, Jonathan A Bernstein..., The New England Journal of Medicine
Patient characteristics that influence efficacy of prophylaxis with rVIII-FS three times per week: a subgroup analysis of the LIPLONG study
Lalezari S, Coppola, A, Lin J, Enriquez MM, Tseneklidou-Stoeter D, Powell J, Ingerslev; LIPLONG Investigators, Haemophilia, 1/1/2014
Phase 3 Study of recominannt factor VIII FC fusion protein in severe hemophilia A
Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa J, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jia..., Blood, 1/1/2014
Efficacy and safeyy of prophylaxis with once weekly BAY 79-4980 compared with thrice �weekly rFVIII-FS in haemophilia A patients A randomized active-controlled, double...
Powell J, Martinowitz U, WIndyga J, Di Minno G, Hellmann A, Pabinger I, Maas Enriquez M, Schwartz L, Ingerslev J; LipLong Investigators, Thromb Haemost, 1/1/2012
Fibrinogen replacement therapy for congenital fibrinogen deficiency
Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ, J Thromb Haemost, 1/1/2011
The use of a single von WIllebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: The US experience
Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld, EJ, Rodriguez N, Wicklund B, Quon D, Aledort L, J Thromb Haemost, 1/1/2011
Pre-surgical pharmacokinetic analysis of von Willebrand Factor/Factor VIII (VWF/FVIII) Concentrate in patients with von Willebrand Disease (VWD) has limited value in d...
DiPaola J, Stefan L, Gill J, Mannucci P, Manco-Johnson M, Bernstein J, Willams N, Bergman G, Haemophilia J, 1/1/2011
von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease
Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M, Haemophilia, 1/1/2011
Improvements in Haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III r...
Ataga KI, Reid M, Ballas Sk, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Socker JW; ICA-17043-10 Study Investigators, British J Haematol, 1/1/2011
Outcome after reduced chemotherapy for intermediate-risk neutroblastoma
Baker DL, Schmidt ML Cohn SL, Maris JM Kibdib WB Buxton A, Stram D, Castleberry RP Shimada H, Sandler A, Shamberger RC, Look AT Reynolds CP, Seeger RC, Matthay KK; Chi..., New Engl JMed, 1/1/2010
Bleeding symptoms and laboratory correlation in patients with severe von WIllebrand disease
Metjian AD, Wang C, Sood SL, Cuker A, Peterson SM, Soucie JM, Konkle BA, HTCN Study Investigators, Haemophilia, 1/1/2009
Argatroban anticoagulation for cardiac surgery with cardiopulmonary bypass in an infance with double outlet right ventricle and a history of heparin-induced thrombocyt...
Cicolo ML, Bernstein J, Collazos JC, Acherman RJ, Restrepo H, Winters JM, Krueger J, Evans WN, Congenit Heart Dis, 1/1/2008
The Development and Management of Inhibitors in Patients with Hemophilia A
Grygotis M, Bernstein J, Aledort L, Grifols Healthcare Patients and Professionals Brochure, 1/1/2006
Nineteen cases of the f(1;22)(p13;q13) acute megakaryblastic leukemia of infants/children and a review of 39 cases: report from a t(1;22) study group
Bernstein J, Dastugue N, Haas OA, Harbott J, Heerema NA, Huret JI, Landman-Parker J, LeBeau MM, Leonard C, Mann G, Pages MP, Perot C, Pirc-Danoewinata H, Roitzheim B, ..., Leukemia, 1/1/2000
Variation in long-term engraftment of a large consecutive series of lambs transplanted in utero with human hematopoetic cells
Bernstein J, Srour E, Boyle DW, Cooper R, Freie BW, Leichty EA, Clapp DW, Biol Blood Marrow Transplant, 1/1/1997
Dicentric (9;20)(p11;q11) identified by fluorescence in situ hybridization in four pediatric acute lymphoblastic leukemia patients
Heerema NA, Maben KD, Bernstein J, Breitfeld PP, Neman RS, Vance GH, Cancer Genet Cytogenet, 1/1/1996
Pregnancy in a patient treated with m-BACOD chemotherapy for high grade non-Hodgkin�s lymphoma
Connolly R, Bernstein J, J Univ Rochester Med Ctr, 1/1/1991
Neuroleptic malignant syndrome: Case report and review of recent literature
Bernstein J, J Univ Rochester Med Ctr, 1/1/1989
The heart in acquired immunodeficiency syndrome
Bernstein J, J UnivRochester Med Ctr, 1/1/1989
Prospective study of respiratory effects of formaldehyde among healthy and asthmatic medical students
Uba G, Pachorek D, Bernstein J, Garabrant DH, Balmes J, Wright WE, Amar RB, Am J Indust Med, 1/1/1989
Join now to see all

Abstracts/Posters

Biochemical and temporal profiling of chemotherapy associated hypoglycemia
Iacono L, Forero L, Bernstein J, Weinstein D, Riba-Wolman R, The Pediatric Academic Societies meeting; 31st Annual Scientific Meeting of the ESPR, 1/1/2019
Large cohort of symptomatic female carriers of Hemophilia A in an extended Native American family
Berkowitz B, Bernstein J, Federizo A, Ulsh P, Thrombosis & Hemostasis Societies of North America, 1/1/2016
Large cohort of symptomatic female carriers of Hemophilia A in an extended Native American family
Berkowitz B, Bernstein J, Federizo A, Ulsh P, Am J Hematol, 1/1/2016
Multiparametric 3.0 Tesla MRI of the brain in Fabry disease
Hanson E, Bernstein J,Roach CJ, Simonelli P, Morris D, Lowery K, Orrison W, Molec Genetics Metabol, 1/1/2012
Case presentation of a patient with Afibrinogenemia
Bernstein J, Federizo A, Thrombosis and Hemostasis Society of North America, 1/1/2012
Case presentation of a patient with Afibrinogenemia
Bernstein J, Federizo A, Am J Hematol, 1/1/2012
Adamts13 content of plasma derived Factor VIII-von Willebrand Factor concentrates
Peyvondi F, Mannucci PM, Valsecchi C, Pontiggia S, Bernstein J, Guazzini S. Retails A, Blood, 1/1/2012
Successful treatment of Factor IX inhibitor complicated by nephrotic syndrome with Rituxan
BernsteinJ, Gupta N, Berkowitz R, Blood, 1/1/2007
Successful treatment of Factor IX inhibitor complicated by nephrotic syndrome with Rituxan
BernsteinJ, Gupta N, Berkowitz R, ASH Annual Meeting, 1/1/2007
Pharmacokinetic analysis of a von Willebrand Factor/Factor VIII (VVWF/FVIII) concentrate in adults and children with von Willebrand Disease (VWD)
Di Paola J, Lethagen S, Gill J, Mannucci P, Bernstein J, Nichols W, Friedman C, Knaub S, Bergman G, Blood, 1/1/2007
Pharmacokinetic analysis of a von Willebrand Factor/Factor VIII (VVWF/FVIII) concentrate in adults and children with von Willebrand Disease (VWD)
Di Paola J, Lethagen S, Gill J, Mannucci P, Bernstein J, Nichols W, Friedman C, Knaub S, Bergman G, ASH Annual Meeting, 1/1/2007
von Willebrand Factor/Factor VIII (VWF/FVIII) concentrate is safe and effective for management of elective surgery in adults and children with von Willebrand Disease(V...
Gill J, Bernstein J, Humate-P Surgery Study Investigators, Blood, 1/1/2007
von Willebrand Factor/Factor VIII (VWF/FVIII) concentrate is safe and effective for management of elective surgery in adults and children with von Willebrand Disease(V...
Gill J, Bernstein J, Humate-P Surgery Study Investigators, ASH Annual Meeting, 1/1/2007
Safety and efficacy of von Willebrand Factor/Factor VIII concentrate for prophylaxis during elective surgery in subjects with von Willebrand disease
Bernstein J, Gill JC, Leissinger CA, Di Paola J, Ragni MV, Shopnik R, Valentino LA, Friedman C, Knaub S, J Thromb Haemost, 1/1/2007
von Willebrand Factor/Factor VIII concentrate effectively prevents excessive bleeding in patients with very Low VWF:RCO plasma levels
Gill JC, Lessinger CA, Di Paola J, Bernstein J, Ragni MV, Valention LA, Knaub S, Friedman C, J Thromb Haemost, 1/1/2007
Pharmacokinetic evaluation of von Willebrand Factor/Factor VIII concentrate (Humate-P) prior to elective surgery in patients with von Willebrand disease
Di Paola J, Gill J, Bernstein J, Leissinger C, Ragni M, Shopnik R, Valentino L, Friedman C, Knaub S, Blood, 1/1/2006
Pharmacokinetic evaluation of von Willebrand Factor/Factor VIII concentrate (Humate-P) prior to elective surgery in patients with von Willebrand disease
Di Paola J, Gill J, Bernstein J, Leissinger C, Ragni M, Shopnik R, Valentino L, Friedman C, Knaub S, ASH Annual Meeting, 1/1/2006
Safety and efficacy of von Willebrand Factor/Factor VIII concentrate (Humate P) for prophylaxis of excessive bleeding during elective surgery in Patients with von Will...
Bernstein J, Gill J, Leissinger C, Di Paola J, Ragni M, Shopnick R, Valentino L, FriedmanC, Knaub S, Humate P Study Group, Blood, 1/1/2006
Safety and efficacy of von Willebrand Factor/Factor VIII concentrate (Humate P) for prophylaxis of excessive bleeding during elective surgery in Patients with von Will...
Bernstein J, Gill J, Leissinger C, Di Paola J, Ragni M, Shopnick R, Valentino L, FriedmanC, Knaub S, Humate P Study Group, ASH Annual Meeting, 1/1/2006
von Willebrand Factor/Factor VIII concentrate (Humate-P) is safe and effective in the prevention of perioperative bleeding in patients with very low von Willebrand Fac...
Gill J, Leissinger C, Di Paola J, Bernstein J, Ragni R, Shopnick L, Valentino L, Knaub S, Friedman C, Blood, 1/1/2006
von Willebrand Factor/Factor VIII concentrate (Humate-P) is safe and effective in the prevention of perioperative bleeding in patients with very low von Willebrand Fac...
Gill J, Leissinger C, Di Paola J, Bernstein J, Ragni R, Shopnick L, Valentino L, Knaub S, Friedman C, ASH Annual Meeting, 1/1/2006
vWF/Factor VIII concentrate (Humate-P) prevents excessive bleeding during and after surgery in pediatric patients with von Willebrand disease (vWD)
Bernstein J, Gill J, Valention L, Ragni M, Knaub S, Friedman C, Pediatric Hematol Oncol, 1/1/2006
vWF/Factor VIII concentrate (Humate-P) prevents excessive bleeding during and after surgery in pediatric patients with von Willebrand disease (vWD)
Bernstein J, Gill J, Valention L, Ragni M, Knaub S, Friedman C, ASPHO, 1/1/2006
Pharmacokinetics of vWF/Factor VIII concentrate (Humate-P) therapy in pediatric patients with von Willebrand Disease (vWD) undergoing elective surgery
Bernstein J, Gill J, Knaub S, Valentino J, Ragni L, Friedman C, Hematology & Oncology, 1/1/2006
Pharmacokinetics of vWF/Factor VIII concentrate (Humate-P) therapy in pediatric patients with von Willebrand Disease (vWD) undergoing elective surgery
Bernstein J, Gill J, Knaub S, Valentino J, Ragni L, Friedman C, ASPHO, 1/1/2006
Join now to see all

Lectures

Sickle cell disease awareness
1/29/2019
vWD in Children, Management of Epistaxis, Group question and answer
1/1/2019
von Willebrand Disease
Bueno Aires, Argentina - 1/3/2018
New Drugs in Hemophilia � Risks and Benefits
1/1/2018
Inhibitors in Adults
1/1/2018
Factor VIII Inhibitors-Inhibitor 101 for Families
1/1/2018
Exercise in Hemophilia
1/1/2018
Drugs Benefits vs Risks
1/1/2018
Inhibitors in hemophilia
Dallas, TX, 2018; Las Vegas, NV, 2019 - 1/1/2017
Transfusion Medicine
Rome, Italy - 1/1/2016
What a hematologist is looking for in a clotting factor/A new generation human cell-line derived rVIII to personalize care and optimize therapy for PUP�s and PTP�s
Zhuhai, China - 1/1/2016
What a hematologist is looking for in a clotting factor Octapharma
San Diego, CA - 1/1/2015
After-Effects of Cancer Treatment on Children and Adolescents
San Diego, CA - 1/1/2012
Promacta use in Pediatric Patients
Use of Social Media with Hemophilia Treatment Centers
Chicago, IL
Clotting abnormalities in Congenital heart patients
New York, NY
Join now to see all